j health sci med / jhsm Journal of Health Sciences and Medicine 2636-8579 MediHealth Academy Yayıncılık 10.32322/jhsm.1831025 Cardiology Kardiyoloji Dirençli hipertansiyon için yeni prediktif biyobelirteçler olarak Sistemik İmmün-Enflamasyon İndeksi ve Sistemik Enflamatuar Yanıt İndeksi: karşılaştırmalı kesitsel çalışma Systemic Immune-inflammation Index (SII) and Systemic Inflammatory Response Index (SIRI) as novel predictors of resistant hypertension https://orcid.org/0000-0002-7280-5137 Aydın Ertan GİRESUN ÜNİVERSİTESİ, TIP FAKÜLTESİ https://orcid.org/0000-0002-6601-8778 Vural Aslı GIRESUN UNIVERSITY, SCHOOL OF MEDICINE https://orcid.org/0000-0002-1656-3778 Yılmaz Emre GIRESUN UNIVERSITY, SCHOOL OF MEDICINE https://orcid.org/0000-0003-4230-3248 Kurt Devrim GIRESUN UNIVERSITY, SCHOOL OF MEDICINE https://orcid.org/0000-0003-2152-0470 Çamcı Sencer GIRESUN UNIVERSITY, SCHOOL OF MEDICINE https://orcid.org/0009-0001-9729-6391 Gök Gökhan GIRESUN UNIVERSITY, SCHOOL OF MEDICINE 01 05 2026 9 1 156 163 11 26 2025 12 21 2025 Copyright © 2018, Journal of Health Sciences and Medicine 2018 Journal of Health Sciences and Medicine

Amaç: Bu çalışma, sistemik bağışıklık-inflamasyon indeksi (SII) ve sistemik inflamatuar yanıt indeksi (SIRI) gibi bileşik inflamasyon indeksleri ile dirençli hipertansiyon arasındaki ilişkiyi araştırarak, bunların öngörücü performansını ve klinik yararını değerlendirmiştir.Materyal ve metod: Nisan 2022'den Ocak 2025'e kadar yürütülen bu karşılaştırmalı kesitsel çalışmaya, 256'sı kontrollü hipertansiyon (HT) ve 244'ü dirençli hipertansiyon (RHT) olan 500 hipertansif hasta dahil edilmiştir. SII ve SIRI, tam kan sayımlarından hesaplanmıştır. Çok değişkenli lojistik regresyon, çeyrek analiz, kısıtlı kübik spline modelleme ve alıcı işletim karakteristiği (ROC) eğrisi analizi gerçekleştirildi.Bulgular: RHT hastaları, anlamlı olarak yüksek SII (480,2'ye karşı 361,7, P

Aims: Resistant hypertension (RHT) accounts for 10-15% of hypertensive patients, and diagnosis and treatment are more complex in these cases, which means a higher risk of cardiovascular complications. Although the effect of chronic systemic inflammation on the pathophysiology of RHT is known, the effective use of biomarkers is limited. This study investigated the relationship between the Systemic Immune-Inflammation Index (SII) and the Systemic Inflammatory Response Index (SIRI), which are composite inflammatory indices that can be used as markers of chronic inflammation, and RHT, testing their clinical utility and predictive value. Methods: Between April 2022 and January 2025, 256 hypertensive patients followed up at our clinic were defined as having controlled hypertension (CHT) and 244 as having RHT, for a total of 500 patients included in this cross-sectional study. SII and SIRI values were calculated from routine blood count results. Data were analyzed and compared using multivariate logistic regression, quartile analysis, limited cubic spline modeling, and receiver operating characteristic (ROC) curve analysis.Results: Significantly higher SII (480.2 vs. 361.7, p

 Resistant hypertension systemic immune-inflammation index systemic inflammatory response index inflammation biomarkers cardiovascular risk Dirençli hipertansiyon sistemik immun-inflamasyon indeksi sistemik inflamatuar yanıt indeksi inlamatuar biyobelirteçler risk sınıflandırması The authors declared that this study has received no financial support. Teşekkür (Türkçe): Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223-237. doi:10.1038/s41581-019-0244-2 de la Sierra A, Ruilope LM, Staplin N, et al. Resistant hypertension and mortality: an observational cohort study. Hypertension. 2024;81:2350-2356. doi:10.1161/HYPERTENSIONAHA.124.23276 McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912-4018. doi:10.1093/eurheartj/ehae178 Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41:1874-2071. doi:10.1097/HJH.0000000000003480 Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the united states. Hypertension. 2019;73:424-431. doi:10.1161/HYPERTENSIONAHA.118. 12191 Parodi R, Brandani L, Romero C, Klein M. Resistant hypertension: diagnosis, evaluation, and treatment practical approach. Eur J Intern Med. 2024;123:23-28. doi:10.1016/j.ejim.2023.12.026 Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125: 1635-1642. doi:10.1161/CIRCULATIONAHA.111.068064 Cardoso CRL, Salles GF. prognostic value of changes in aortic stiffness for cardiovascular outcomes and mortality in resistant hypertension. Hypertension. 2022;79:447-456. doi:10.1161/HYPERTENSIONAHA. 121.18498 Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57:132-140. doi:10.1161/HYPERTENS IONAHA.110.163576 Tsioufis C, Kordalis A, Flessas D, et al. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens. 2011;2011:642416. doi:10.4061/2011/642416 Nishiyama A. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Hypertens Res. 2019;42:293-300. doi:10.1038/s41440-018-0158-6 Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55:500-507. doi:10.1161/HYPERTENSIONAHA. 109.145094 Saco-Ledo G, Valenzuela PL, Ruilope LM, Lucia A. Physical exercise in resistant hypertension: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:893811. doi:10.3389/fcvm.2022.893811 Wang A, Tian X, Zuo Y, et al. Monocyte-to-lymphocyte ratio is associated with the presence and severity of resistant hypertension. J Clin Hypertens. 2022;24:1022-1029. Cicero AFG, Veronesi M, Fogacci F. Dietary intervention to improve blood pressure control: beyond salt restriction. High Blood Press Cardiovasc Prev. 2021;28:547-553. doi:10.1007/s40292-021-00474-6 Blumenthal JA, Hinderliter AL, Smith PJ, et al. Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial. Circulation. 2021;144:1212-1226. doi:10.1161/CIRCULATIONAHA.121.055329 Ozemek C, Tiwari S, Sabbahi A, Carbone S, Lavie CJ. Impact of therapeutic lifestyle changes in resistant hypertension. Prog Cardiovasc Dis. 2020;63:4-9. doi:10.1016/j.pcad.2019.11.012 Yamada T, Kimura-Koyanagi M, Sakaguchi K, Ogawa W, Tamori Y. Obesity and risk for its comorbidities diabetes, hypertension, and dyslipidemia. Sci Rep. 2023;13:2346. doi:10.1038/s41598-023-29276-7 Filippou C, Tatakis F, Polyzos D, et al. Overview of salt restriction in the Dietary Approaches to Stop Hypertension (DASH) and the mediterranean diet for blood pressure reduction. Rev Cardiovasc Med. 2022;23:36. doi:10.31083/j.rcm2301036 Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis. Heart. 2019;105: 98-105. doi:10.1136/heartjnl-2018-313599 Tompson AC, Ward AM, McManus RJ, et al. Acceptability and psychological impact of out-of-office monitoring to diagnose hypertension. Br J Gen Pract. 2019;69:e389-e397. doi:10.3399/bjgp19X70 2221 Kasiakogias A, Tsioufis C, Dimitriadis K, et al. Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives. J Hum Hypertens. 2018;32:487-493. doi:10.1038/s41371-018-0065-y Wei FF, Zhang ZY, Huang QF, Staessen JA. Diagnosis and management of resistant hypertension: state of the art. Nat Rev Nephrol. 2018;14:428-441. doi:10.1038/s41581-018-0006-6 Hu B, Yang XR, Xu Y, et al. Systemic Immune-Inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20:6212-6222. doi:10.1158/1078-0432.CCR-14-0442 Qi X, Li J, Deng H, et al. Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma. Oncotarget. 2016;7: 45283-45301. doi:10.18632/oncotarget.9942 Dudenbostel T, Calhoun DA. Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension. Am J Hypertens. 2017; 30:103-109. doi:10.1093/ajh/hpw105 Zhao D, Liu H, Dong P, Zhao J. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. Int J Cardiol. 2017;233:113-117. doi:10.1016/j.ijcard.2016.12.158 Bozkurt B, Aguilar D, Deswal A, et al. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure. Circulation. 2016;134:e535-e578. doi:10.1161/CIR.0000000000000450 Rosa J, Zelinka T, Petrák O, et al. Should all patients with resistant hypertension receive spironolactone? Curr Hypertens Rep. 2016;18:81. doi:10.1007/s11906-016-0690-1 Fadl Elmula FE, Jin Y, Yang WY, et al. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Press. 2015;24:263-274. doi:10.3109/08037051.2015.1058595